GeneOne Life Science (011000): Korean Health Care stock

What the company does

GeneOne Life Science is a South Korean biotech company focused on developing DNA-based medicines, including therapeutic and preventive treatments for infectious diseases and cancer.

Its products are aimed at patients and healthcare providers, and the company works within the broader pharmaceutical and biotechnology supply chain. Listed on KOSPI, South Korea's main stock exchange, GeneOne is currently in an active research and development phase, with its pipeline of DNA medicines representing the core of its business activity.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$16.7M

▼ −35.5% YoY

Operating profit · FY2025

−US$31.9M

Loss widened

Net income · FY2025

−US$37.6M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$29.1M(₩40.2B)	US$25.9M(₩35.7B)	US$16.7M(₩23B)
Operating profit	−US$35M(−₩48.4B)	−US$31.2M(−₩43B)	−US$31.9M(−₩44B)
Net income	−US$56.4M(−₩77.8B)	−US$35.2M(−₩48.5B)	−US$37.6M(−₩51.9B)

Revenue

FY2023US$29.1M
FY2024US$25.9M
FY2025US$16.7M

Operating profit

FY2023−US$35M
FY2024−US$31.2M
FY2025−US$31.9M

Net income

FY2023−US$56.4M
FY2024−US$35.2M
FY2025−US$37.6M

Key ratios (FY2025)

ROE

-126.8%

Debt/Eq

191.5%

Op. margin

-191.1%

Net margin

-225.0%

Rev. YoY

▼ −35.5%

Filings

All disclosures · English when translated

Price charts coming soon

Interactive price history isn't here yet. Would you use it?